아리바이오랩

261780KOSDAQ자연과학 및 공학 연구개발업

40.7 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment17.2 / 25

Momentum4.0 / 20

Disclosure12.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Declined 10.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Chabaksin Research Institute is a biotech company specializing in the development of vaccines and immunotherapies using advanced technologies such as virus-like particles (VLP), liposomes, and immune checkpoint inhibitors (ICI). The company focuses on immunological research, antigen presentation, and apoptosis-related mechanisms to develop new drugs for infectious diseases and cancer.

Number of Employees

49people

Average Salary

63.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

5.59Industry Average 2.520.0Point

2.2x industry avg (risky)

ROE

-81.07Industry Average -32.093.5Point

2.5x industry avg (excellent)

Debt Ratio

14.65Industry Average 7.310.0Point

2.0x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼15.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼52.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -39.4% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 2Negative 0Average Sentiment Score 68.8

Neutral
아리바이오랩, 20억원 유상증자…아리바이오에 제3자배정
아리바이오랩의 유상증자 결정은 자금 조달 필요성을 반영하지만, 직접적인 시장 영향은 제한적입니다.
Neutral
아리바이오그룹 "광진실업 등 일부 기업 연계설 사실무근…3사 협력 .....
아리바이오그룹은 특정 기업들과의 인수합병 루머를 부인하며, 시장 내 소문 확산에 대해 언급했으나 직접적인 주식 영향은 없다고 판단됨.
Positive
소룩스, '아리바이오홀딩스'로 새 출발…글로벌 바이오 그룹 도약 본.....
아리바이오랩의 자회사 소룩스가 새로운 바이오 그룹 '아리바이오홀딩스'로 전환하며 알츠하이머 치료제 개발 성공을 바탕으로 사업 확장을 가속화하고 있다.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 2,365Won52-week high 5,70052-week low 2,300

1-month return1.0Point

1m -10.92% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 1Neutral 7Negative 0

Positive주요사항보고서(유상증자결정)2026-07-23
Neutral주주총회소집공고2026-07-15
Neutral의결권대리행사권유참고서류2026-07-15
Neutral[기재정정]주주총회소집결의2026-07-15
Neutral증권발행결과(자율공시)2026-06-30